



Arsanis to Present at the Cowen and Company 36th Annual Health Care Conference

WALTHAM, Mass. and VIENNA, Austria (March 2, 2016) – Arsanis, Inc., a clinical-stage biopharmaceutical company focused on monoclonal antibody approaches for the prevention and treatment of serious infectious diseases, today announced that René Russo, PharmD, BCPS, chief development officer, will present a company overview at the Cowen and Company 36th Annual Health Care Conference in Boston.

The presentation will take place on Tuesday, March 8, 2016, at 1:30 p.m. EST.

About Arsanis, Inc.

Arsanis is a clinical-stage company creating precision monoclonal antibodies for the prevention and treatment of serious bacterial infections not effectively controlled by currently available treatments. The company applies its extensive knowledge of infectious disease biology to design optimal human monoclonal antibodies that precisely and directly target pathogens and/or support host defenses against the infecting bacteria and their toxins. The company is building a broad product pipeline addressing the most important Gram-positive and Gram-negative bacterial pathogens threatening hospitalized and high-risk patients. Its lead therapeutic candidate, ASN100, is aimed at the prevention and treatment of serious *Staphylococcus aureus* infections and entered a Phase I clinical trial in the fall in 2015, with a Phase II study anticipated to begin in 2016. Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and pre-clinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH). For more information, please visit the Arsanis website at www.arsanis.com.

###

Media Contact:

Ten Bridge Communications

Krystle Gibbs

Krystle@tenbridgecommunications.com, 508-479-6358

Investor Contact:

Arsanis, Inc.

Mike Gray

mike.gray@arsanis.com, 781-819-5201